Compass Therapeutics, Inc. (CMPX) research
Compass Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.24
- As of
Compass Therapeutics, Inc. (CMPX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.
As of . Source: SEC EDGAR filings for CMPX. Method and limitations.
Share the CMPX intelligence card
See CMPX live in the terminal
Track CMPX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CMPX terminal, freeActive signals for CMPX
- highCONSENSUS_BUY
5 tracked funds increased CMPX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased CMPX this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in CMPX
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +457% to CMPX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3279% to CMPX (2026Q2)
FREE, NO ACCOUNT
Every signal on CMPX, as it fires
You are seeing 5 of 27 signals recorded on CMPX since 2026-06-09.
The five above landed across 2 days. The other 22 were recorded on 3 other days. 19 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CMPX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 20454B104 · 2026Q2 | $10.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 20454B104 · 2026Q2 | $7.8M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 20454B104 · 2026Q2 | $1.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 20454B104 · 2026Q2 | $701K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 20454B104 · 2026Q2 | $448K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CMPX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CMPX against its peers
CMPX's return on equity of -33.8% ranks in the 48th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | CMPX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 44.6M USD | 8 | 17 |
| Operating margin | n/a | -130.7% | n/a | 15 |
| Net margin | n/a | -113.7% | n/a | 16 |
| Return on equity | -33.8% | -33.5% | 48 | 21 |
Peers (24): LXEO, EVMN, EBS, IPSC, STRO, EYPT, ENTA, XFOR, SION, OCGN, OBIO, SABS, QTTB, ABEO, DMAC, RCKT, MYGN, IFRX, AGEN, VNDA, IKT, BBOT, FENC, BNTC. Left out: RZLT (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CMPX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CMPX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CMPXand get the insider, 13F, options, and confluence read in one view.